Cytokinetics (CYTK) Tops Q4 EPS by 8c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $68.78 -1.63%
Revenue Growth %: +1,966.3%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +1,966.3%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($0.24), $0.08 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $10.49 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Arrive AI and DXC Technology partner to bring delivery tech to factories
- Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
